Array BioPharma Inc. (Nasdaq:ARRY) will report financial results for the fourth quarter and full year of fiscal 2012 on Monday, August 13, 2012, and will hold a conference call on Tuesday, August 14, 2012 at 9:00 a.m. eastern time to discuss these results. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
Conference Call Information
|Tuesday, August 14, 2012|
|9:00 a.m. eastern time|
Webcast & Conference Call Slides:
A replay of the call will be available as a webcast on www.arraybiopharma.com.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Array has four core proprietary clinical programs: ARRY-614 for myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded clinical programs including two MEK inhibitors in Phase 2: selumetinib with AstraZeneca and MEK162 with Novartis. For more information on Array, please go to www.arraybiopharma.com.